2
Seminars in Immunology 20 (2008) 205–206 Contents lists available at ScienceDirect Seminars in Immunology journal homepage: www.elsevier.com/locate/ysmim Editorial Lymphoid myeloid lineage specification The hematopoietic system has long been a paradigm to study how adult type stem cells diversify into different lineages. Once hematopoietic stem cells (HSCs) lose their ability to self renew they become progressively restricted in their differentiation poten- tial. Diversification is a hierarchical process that can be visualized in lineage trees. This process is driven by transcription factors and microRNAs, whose activities can respond to signaling from the microenvironment. Once changes in gene expression are induced they are stabilized by chromatin modifications. Com- mitment is typically preceded by the low level expression in multipotent progenitors of lineage-restricted genes. During differ- entiation expression of these genes is successively either reinforced or repressed, leading to the formation of specialized cells that exhibit markers and functions characteristic for a particular lineage. There has been much controversy about how myeloid and lym- phoid lineages, the constituents of the innate and adaptive immune system respectively, branch from each other. Although the progress achieved in this area over the past few years have helped clarify- ing some of the issues, things have become also more complicated. The first two reviews start by discussing the latest models of early lineage specification. The following four reviews mechanisms driv- ing the formation B cells, T cells and myeloid cells, focusing on the role of transcription factors and micro RNAs. The issue ends with a review on the chromatin changes induced during transcription factor induced commitment of myeloid cells. The articles of Luc et al. and Lai and Kondo address the issue of how the earliest hematopoietic progenitors, cells within the so- called LSK compartment (Lin-/low, Sca-1+, Kit+) become restricted in their developmental potential. It is now clear that the first step is the formation of a subset of LSK cells that loses the ability to form erythrocytes and megakaryocytes, but retains the potential to generate all cells of the immune system. However, what initially appeared to be a series of simple binary decisions turned out to be more a gradual change in differentiation probabilities, complicat- ing attempts to draw a well defined and uncontested early lineage tree. In addition, although much has been learned from defining the cells’ differentiation potential in vitro or after transplantation these assays only partially reconstruct the cells differentiation potential in vivo. As Luc et al. put it: future efforts are needed for the ‘devel- opment of reliable reporter systems allowing dynamic tracking of the commitment process’ The regulatory network that defines the B cell lineage is one of the best understood to date. The reviews of Lukin et al. and Laslo et al. describe the fundamental role of the transcription factor EBF1. This factor becomes upregulated at the common lymphoid progen- itor stage and is embedded in a regulatory network that involves E2A and Pax5. The network, which is stabilized by feedback loops, ensures total repression of lineage inappropriate gene expression, such as myeloid or T cell genes. Laslo et al. also extensively discusses the role of PU.1 and C/EBP as primary lineage determinants that specify macrophage and granulocyte development. They review data from their own lab showing that a second layer of transcrip- tion factors (‘secondary lineage determinants’) refine the decisions within the myeloid compartment, leading to the alternative forma- tion of macrophages or granulocytes. Finally, they discuss the role of two microRNA systems that modulate the expression of myeloid associated transcription factors, leading to a reinforcement of the formation of either macrophages or granulocytes. Rothenberg and Scripture-Adams discuss T cell fate choice, sin- gling out GATA-3, PU.1 and Notch as key determinants. Here, Notch plays a unique role as a receptor that becomes a transcription factor following signaling induced by ligand that is expressed by thymic stromal cells. Notch signaling inhibits alternative choices in a sequential manner, with B cell developmental potential being lost before myeloid/dendritic and NK cell potentials. However, as they point out, ‘Notch is not a Boolean operator that determines T lineage fate at a stroke, but a quantitatively modulated participant in protracted lineage decisions’. Like at the branching between B and myeloid lineage cells, myeloid fate decisions are effected by the expression PU.1 and C/EBP, and are counteracted by Notch and GATA-3. T cell commitment thus provides a particularly clear example of how cell fate decisions are influenced by the cells’ microenvironment, directly feeding into antagonistic regulatory networks. The article by Greig et al. discusses the role of Myb, a tran- scription factor originally identified as an oncogene in acute avian leukemia. Myb, which initially was thought to be required for the formation of definitive HSCs in the fetal liver, is now thought to be mainly needed for their expansion and perhaps differentiation. This factor is surprisingly versatile in its recurrent use in differ- ent lineages and at different stages of development. Besides its role for red blood cell precursor proliferation and megakaryocyte function it is required for the progression of early T and B cell devel- opment. The latter role is attenuated by mir150, a microRNA that inhibits Myb expression. However, there is still surprisingly little known about how Myb interacts with the various lineage specific regulatory networks, knowledge that is essential to understand its versatility. The last review, by Bonifer et al., discusses the interplay between the myeloid associated transcription factor PU.1 and chromatin components in the specification of myeloid cells. Here, studies on the macrophage restricted CSF-1 (M-CSF) receptor gene have 1044-5323/$ – see front matter © 2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.smim.2008.08.005

Lymphoid myeloid lineage specification

Embed Size (px)

Citation preview

Page 1: Lymphoid myeloid lineage specification

Seminars in Immunology 20 (2008) 205–206

Contents lists available at ScienceDirect

Seminars in Immunology

journa l homepage: www.e lsev ier .com/ locate /ysmim

Editorial

Lymphoid myeloid lineage specification

hhttiatimmeoe

psaiTliraf

ociiftamitcaiot

taTi

Eestsdtwtoaf

gpftiltliataemn

slfbTerfoikrv

1d

The hematopoietic system has long been a paradigm to studyow adult type stem cells diversify into different lineages. Onceematopoietic stem cells (HSCs) lose their ability to self renewhey become progressively restricted in their differentiation poten-ial. Diversification is a hierarchical process that can be visualizedn lineage trees. This process is driven by transcription factorsnd microRNAs, whose activities can respond to signaling fromhe microenvironment. Once changes in gene expression arenduced they are stabilized by chromatin modifications. Com-

itment is typically preceded by the low level expression inultipotent progenitors of lineage-restricted genes. During differ-

ntiation expression of these genes is successively either reinforcedr repressed, leading to the formation of specialized cells thatxhibit markers and functions characteristic for a particular lineage.

There has been much controversy about how myeloid and lym-hoid lineages, the constituents of the innate and adaptive immuneystem respectively, branch from each other. Although the progresschieved in this area over the past few years have helped clarify-ng some of the issues, things have become also more complicated.he first two reviews start by discussing the latest models of earlyineage specification. The following four reviews mechanisms driv-ng the formation B cells, T cells and myeloid cells, focusing on theole of transcription factors and micro RNAs. The issue ends withreview on the chromatin changes induced during transcription

actor induced commitment of myeloid cells.The articles of Luc et al. and Lai and Kondo address the issue

f how the earliest hematopoietic progenitors, cells within the so-alled LSK compartment (Lin-/low, Sca-1+, Kit+) become restrictedn their developmental potential. It is now clear that the first steps the formation of a subset of LSK cells that loses the ability toorm erythrocytes and megakaryocytes, but retains the potentialo generate all cells of the immune system. However, what initiallyppeared to be a series of simple binary decisions turned out to beore a gradual change in differentiation probabilities, complicat-

ng attempts to draw a well defined and uncontested early lineageree. In addition, although much has been learned from defining theells’ differentiation potential in vitro or after transplantation thesessays only partially reconstruct the cells differentiation potentialn vivo. As Luc et al. put it: future efforts are needed for the ‘devel-pment of reliable reporter systems allowing dynamic tracking ofhe commitment process’

The regulatory network that defines the B cell lineage is one of

he best understood to date. The reviews of Lukin et al. and Laslo etl. describe the fundamental role of the transcription factor EBF1.his factor becomes upregulated at the common lymphoid progen-tor stage and is embedded in a regulatory network that involves

tco

044-5323/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.oi:10.1016/j.smim.2008.08.005

2A and Pax5. The network, which is stabilized by feedback loops,nsures total repression of lineage inappropriate gene expression,uch as myeloid or T cell genes. Laslo et al. also extensively discusseshe role of PU.1 and C/EBP� as primary lineage determinants thatpecify macrophage and granulocyte development. They reviewata from their own lab showing that a second layer of transcrip-ion factors (‘secondary lineage determinants’) refine the decisionsithin the myeloid compartment, leading to the alternative forma-

ion of macrophages or granulocytes. Finally, they discuss the rolef two microRNA systems that modulate the expression of myeloidssociated transcription factors, leading to a reinforcement of theormation of either macrophages or granulocytes.

Rothenberg and Scripture-Adams discuss T cell fate choice, sin-ling out GATA-3, PU.1 and Notch as key determinants. Here, Notchlays a unique role as a receptor that becomes a transcription

actor following signaling induced by ligand that is expressed byhymic stromal cells. Notch signaling inhibits alternative choicesn a sequential manner, with B cell developmental potential beingost before myeloid/dendritic and NK cell potentials. However, ashey point out, ‘Notch is not a Boolean operator that determines Tineage fate at a stroke, but a quantitatively modulated participantn protracted lineage decisions’. Like at the branching between Bnd myeloid lineage cells, myeloid fate decisions are effected byhe expression PU.1 and C/EBP�, and are counteracted by Notchnd GATA-3. T cell commitment thus provides a particularly clearxample of how cell fate decisions are influenced by the cells’icroenvironment, directly feeding into antagonistic regulatory

etworks.The article by Greig et al. discusses the role of Myb, a tran-

cription factor originally identified as an oncogene in acute avianeukemia. Myb, which initially was thought to be required for theormation of definitive HSCs in the fetal liver, is now thought toe mainly needed for their expansion and perhaps differentiation.his factor is surprisingly versatile in its recurrent use in differ-nt lineages and at different stages of development. Besides itsole for red blood cell precursor proliferation and megakaryocyteunction it is required for the progression of early T and B cell devel-pment. The latter role is attenuated by mir150, a microRNA thatnhibits Myb expression. However, there is still surprisingly littlenown about how Myb interacts with the various lineage specificegulatory networks, knowledge that is essential to understand itsersatility.

The last review, by Bonifer et al., discusses the interplay betweenhe myeloid associated transcription factor PU.1 and chromatinomponents in the specification of myeloid cells. Here, studiesn the macrophage restricted CSF-1 (M-CSF) receptor gene have

Page 2: Lymphoid myeloid lineage specification

2 muno

sclqa

ubo

smdm

06 Editorial / Seminars in Im

hown that commitment to the myeloid lineage is a two-step pro-ess that is initiated by binding of PU.1 to the CSF-1R promoter andater extended to the enhancer of the gene. This leads to the subse-uent chromatin remodeling of the respective regulatory elements

nd epigenetic stabilization of the changes induced.

The topics discussed in this issue are important not only for thenderstanding of fundamental processes of lineage specification,ut are also relevant for understanding leukemogeneiss, as manyf the transcription factors discussed can act as oncogenes, or in

logy 20 (2008) 205–206

ome cases, as tumor suppressors. Moreover, as succinctly sum-arized by Laslo et al. ‘progress in this area will also facilitate the

irected and efficient generation of specific immune cells and theiranipulation for cell based therapies’.

Thomas GrafCancer and Differentiation, CRG,

Barcelona, SpainE-mail address: [email protected]